Moreover, PTPRJ and CD98hc inverse correlation, assessed by interrogating canEvolve database in a large number of lung cancer patients, not only proposes these proteins as candidate biomarkers of tumor aggressiveness but also encourages the development of novel targeted therapies for the treatment of cancer. The gene discussed is SLC3A2; the disease is neoplasm.